文献速递其他结缔组织病

艾加莫德在免疫介导坏死性肌病人源化小鼠模型中恢复肌肉功能

Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

在免疫介导坏死性肌病(IMNM)人源化小鼠模型中,艾加莫德快速降低血清和肌肉中的总IgG及致病性抗HMGCR自身抗体水平;预防性给药可防止肌纤维坏死和肌力丧失,治疗性给药可阻止进一步坏死并促进肌纤维再生,使肌力恢复正常。

要点

  • 艾加莫德降低血清总IgG及抗HMGCR自身抗体水平(血清P<0.0001,肌肉P<0.001)。
  • 预防性给药防止肌纤维坏死(P<0.05)并避免肌力丧失(P<0.05)。
  • 治疗性给药阻止进一步坏死、促进肌纤维再生(P<0.05),肌力恢复正常(P<0.01)。

核心结论

  • 在IMNM人源化小鼠模型中,艾加莫德降低循环IgG水平(包括致病性抗HMGCR+IgG自身抗体),阻止进一步坏死并促进肌纤维再生。
  • 作者认为这些结果支持通过临床试验研究艾加莫德在IMNM患者中的治疗疗效。

研究设计与样本

  • 在C5缺陷(C5def)或Rag2缺陷(Rag2-/-)小鼠中,通过共注射来自IMNM患者的抗HMGCR+IgG和人补体诱导疾病。
  • C5def小鼠在预防性设置中接受艾加莫德皮下注射治疗;Rag2-/-小鼠在抗HMGCR+IgG注射诱导疾病后,于治疗性设置中接受艾加莫德治疗。
  • 监测小鼠血清和肌肉组织中的抗HMGCR自身抗体水平,对肌肉切片进行组织学分析,通过抓力测试或电刺激后腓肠肌力量测量评估肌力。

主要发现

  • 艾加莫德在血清(P<0.0001)和肌肉(P<0.001)中快速降低总IgG水平,包括致病性抗HMGCR自身抗体水平。
  • 在预防性设置中,艾加莫德防止肌纤维坏死(P<0.05),从而避免肌力丧失(P<0.05)。
  • 在治疗性设置中,艾加莫德阻止进一步坏死并允许肌纤维再生(P<0.05),肌力恢复正常(P<0.01)。

临床怎么用

  • 原文结论为这些结果支持通过临床试验研究艾加莫德在IMNM患者中的治疗疗效,未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Immune-mediated necrotizing myopathies (IMNMs) are severe forms of myositis often associated with pathogenic anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) autoantibodies (aAbs). Efgartigimod is an engineered human IgG1 Fc fragment that antagonizes the neonatal Fc receptor (FcRn), thereby preventing recycling and promoting lysosomal degradation of IgG, including aAbs. We evaluated the therapeutic effects of IgG reduction by efgartigimod in a humanized murine model of IMNM. METHODS: Disease was induced in C5-deficient (C5def) or Rag2-deficient (Rag2-/-) mice receiving co-injections of anti-HMGCR+ IgG from an IMNM patient and human complement. C5def mice were treated in a preventive setting with s.c. injections of efgartigimod and Rag2-/- mice in a curative setting after disease was induced by anti-HMGCR+ IgG injections. Anti-HMGCR aAbs levels were monitored in mouse serum and muscle tissue. Histological analysis was performed on muscle sections. Muscle force was assessed by grip test or measurement of gastrocnemius strength upon electrostimulation. RESULTS: Administration of efgartigimod rapidly reduced total IgG levels, including the level of pathogenic anti-HMGCR aAbs, in both serum (P < 0.0001) and muscle (P < 0.001). In the preventive setting, efgartigimod prevented myofibre necrosis (P < 0.05), thus precluding loss of muscle strength (P < 0.05). In the therapeutic setting, efgartigimod prevented further necrosis and allowed muscle fibre regeneration (P < 0.05). Hence, muscle strength returned to normal (P < 0.01). CONCLUSION: Efgartigimod reduces circulating IgG levels, including pathogenic anti-HMGCR+ IgG aAbs, in a humanized mouse model of IMNM, preventing further necrosis and allowing muscle fibre regeneration. These results support investigating the therapeutic efficacy of efgartigimod through a clinical trial in IMNM patients.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Julien S, van der Woning B, De Ceuninck L, et al. Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy. Rheumatology (Oxford). 2023. PMID: 37335864. doi:10.1093/rheumatology/kead298

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。